Promising Healthcare Stocks To Watch Today – April 17th

UnitedHealth Group, Alphabet, Elevance Health, Johnson & Johnson, and Amgen are the five Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. Healthcare stocks are shares of companies operating in the healthcare industry, including pharmaceutical firms, biotechnology companies, medical device manufacturers, and healthcare service providers. Investors in these stocks gain exposure to the sector’s growth potential, driven by factors such as aging populations, technological advancements, and evolving regulatory environments. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

NYSE UNH traded down $131.56 on Thursday, hitting $453.48. 18,534,178 shares of the company traded hands, compared to its average volume of 4,369,527. The business’s 50 day moving average price is $516.05 and its 200-day moving average price is $542.41. The company has a market capitalization of $414.80 billion, a price-to-earnings ratio of 29.35, a P/E/G ratio of 1.37 and a beta of 0.61. UnitedHealth Group has a 52-week low of $438.50 and a 52-week high of $630.73. The company has a current ratio of 0.83, a quick ratio of 0.91 and a debt-to-equity ratio of 0.74.

Alphabet (GOOGL)

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube.

Shares of GOOGL traded down $1.85 during mid-day trading on Thursday, reaching $151.48. 18,874,136 shares of the company’s stock traded hands, compared to its average volume of 28,219,381. The stock’s 50-day moving average is $166.53 and its two-hundred day moving average is $175.98. The stock has a market cap of $1.85 trillion, a P/E ratio of 18.84, a P/E/G ratio of 1.34 and a beta of 1.03. Alphabet has a 12 month low of $140.53 and a 12 month high of $207.05. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.84 and a quick ratio of 1.84.

Elevance Health (ELV)

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

ELV traded down $7.17 on Thursday, reaching $427.87. 2,154,072 shares of the stock were exchanged, compared to its average volume of 1,444,495. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The company’s 50-day moving average price is $415.54 and its 200 day moving average price is $412.33. Elevance Health has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The firm has a market capitalization of $96.86 billion, a PE ratio of 16.71, a PEG ratio of 1.18 and a beta of 0.77.

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Shares of NYSE:JNJ traded up $4.51 during midday trading on Thursday, reaching $158.42. 5,054,994 shares of the company’s stock were exchanged, compared to its average volume of 7,943,408. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm’s 50 day simple moving average is $159.40 and its two-hundred day simple moving average is $155.10. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $381.76 billion, a price-to-earnings ratio of 23.83, a P/E/G ratio of 2.56 and a beta of 0.49.

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Shares of AMGN traded down $5.26 during mid-day trading on Thursday, reaching $277.38. 2,700,129 shares of the company’s stock were exchanged, compared to its average volume of 2,784,374. The company has a market cap of $149.13 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.63 and a beta of 0.59. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a 50-day simple moving average of $303.78 and a two-hundred day simple moving average of $294.82. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85.